Interpretation of Chinese expert consensus statement on cardiac biomarkers for monitoring and management of cardiovascular toxicity in cancer therapy (2024 edition)

In recent years, advances in the treatment of malignant tumors have significantly extended the survival of patients with cancer. As tumors increasingly present as chronic diseases, the cardiovascular toxicity associated with cancer treatment has become more prominent, impacting treatment efficacy and patient survival. As a result, cardio-oncology has emerged as a rapidly growing discipline; however, cardiovascular diseases in patients with cancer often have an insidious onset, and early identification and treatment are frequently overlooked. The Chinese expert consensus is based on a systematic review of the rational application of cardiac biomarkers for cardiovascular disease risk stratification, early identification, and patient screening throughout the course of cancer treatment. The consensus provides 26 recommendations, each supported by evidence and explanations, aiming to improve the early diagnosis and treatment of cardiovascular disease in patients with cancer. These guidelines provide a basis for standardized screening and management of cardiovascular toxicity related to cancer treatment through the reasonable application of cardiac biomarkers. This review discusses key points of this consensus.